{'fraction_non_alphanumeric': 0.03600654664484452, 'fraction_numerical': 0.0016366612111292963, 'mean_word_length': 5.725274725274725, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 2, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Incremental cost of non‐invasive prenatal diagnosis versus invasive prenatal diagnosis of fetal sex in England

Fetal sex determination is performed for women who carry X‐linked conditions, for example Duchenne muscular dystrophy (DMD), or those associated with ambiguous genitalia, for example congenital adrenal hyperplasia (CAH). Non‐invasive prenatal diagnosis (NIPD) using cell‐free fetal DNA (cffDNA) in maternal plasma is an alternative to invasive prenatal diagnosis (IPD), which carries a 1% risk of miscarriage. This study aimed to evaluate the incremental cost of NIPD compared with IPD of fetal sex.